Baseline Anti-Citrullinated Protein Antibody Status and Response to Abatacept or Non-TNFi Biologic/Targeted-Synthetic DMARDs: US Observational Study of Patients with RA-Reference-Cited by-同舟云学术

Baseline Anti-Citrullinated Protein Antibody Status and Response to Abatacept or Non-TNFi Biologic/Targeted-Synthetic DMARDs: US Observational Study of Patients with RA

Published:2021-12-23 Issue: Volume: Page:
ISSN:2198-6576
Container-title:Rheumatology and Therapy
language:en
Short-container-title:Rheumatol Ther

Author:

Harrold Leslie R.,Connolly Sean E.,Wittstock Keith,Zhuo Joe,Kelly Sheila,Lehman Thomas,Shan Ying,Rebello Sabrina,Guo Lin,Khaychuk Vadim

Funder

Bristol-Myers Squibb

CorEvitas, LLC

Publisher

Springer Science and Business Media LLC

Subject

Immunology and Allergy,Rheumatology

Link

https://link.springer.com/content/pdf/10.1007/s40744-021-00401-0.pdf

Reference34 articles.

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376:1094–108.

2. van der Helm-van Mil AHM, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther. 2005;7:R949–58.

3. Hecht C, Englbrecht M, Rech J, et al. Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA. Ann Rheum Dis. 2015;74:2151–6.

4. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2016;68:1–26.

5. Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685–99.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biologics or Janus Kinase Inhibitors in Rheumatoid Arthritis Patients Who are Insufficient Responders to Conventional Anti-Rheumatic Drugs;Drugs;2024-07-01

2. Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study;RMD Open;2024-06

3. The impact of autoantibodies on the efficacy of biological disease-modifying anti-rheumatic drugs in rheumatoid arthritis: meta-analysis of randomized controlled trials;Rheumatology;2024-02-16

4. Comparative effectiveness of abatacept versus TNF inhibitors in rheumatoid arthritis patients who are ACPA and shared epitope positive;Advances in Rheumatology;2024-01-19

5. Should complete B cell depletion be maintained in patients treated long-term with rituximab for rheumatoid arthritis?;Rheumatology;2023-10-04